Lonza Group AG (LONN.SW)

526.40 +6.20 (+1.19%) 收市：05:31PM CEST

Lonza Group AG

Muenchensteinerstrasse 38
Basel 4002
Switzerland
41 61 316 81 11
https://www.lonza.com

版塊: Healthcare
行業: Diagnostics & Research
全職員工: 18,000

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Albert M. Baehny	Interim CEO & Chairman	410.69k	無	1952
Mr. Philippe Deecke	Chief Financial Officer	無	無	1972
Ms. Maria Soler Nunez	Head of Group Operations	無	無	1969
Mr. Dirk Oehlers	Vice President of Investor Relations	無	無	無
Mr. Andreas Bohrer	Group General Counsel & Company Secretary	無	無	無
Ms. Kim Harrelson	Head of Ethics & Compliance, ERM and Corporate Responsibility	無	無	無
Ms. Victoria Morgan	Head of External Communications	無	無	無
Ms. Jennifer Clancy	Senior Director of Global Marketing	無	無	無
Ulrike Kaeppler	Chief Human Resources Officer	無	無	無
Dr. Matthias Hofmann	Head of Corporate Environment, Health, Safety & Global Sustainability	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 CHF。

描述

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.

公司管治

截至 2024年5月1日 止，Lonza Group AG 的 ISS 管治質素評分為 1。 Pillar 分數正在審核中：5；董事會：1；股東權利：1；現金賠償：1。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。